Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MonoSol Rx and Midatech have launched strategic joint venture, MidaSol Therapeutics, focused on partnering and licensing of innovative diabetes therapies.
Subscribe to our email newsletter
MidaSol non-injectable Insulin addresses the unmet need of diabetic patients who are dependent on insulin injections by providing a more convenient, non invasive, treatment option.
The companies are conducting a Phase I clinical study of their most advanced candidate which utilizes insulin-passivated gold glyconanoparticles (MidaForm insulin) formulated into PharmFilm for buccal delivery.
Results of the Phase I study are expected in the first half of 2012.
MonoSol president and CEO Mark Schobel said the MidaSol launch is designed to accelerate the commercialization of the innovative insulin, GLP-1 and insulin/GLP-1 products for the treatment of diabetes.